低侵入性肺表面活性物质治疗技术治疗新生儿呼吸窘迫综合征有效性和安全性的Meta分析

霍梦月; 梅花; 张钰恒; 刘春枝; 胡亚楠; 宋丹

doi:10.7499/j.issn.1008-8830.2001043

PDF(1543 KB)

HTML

中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (7) : 721-727. DOI: 10.7499/j.issn.1008-8830.2001043

论著·临床研究

低侵入性肺表面活性物质治疗技术治疗新生儿呼吸窘迫综合征有效性和安全性的Meta分析

霍梦月, 梅花, 张钰恒, 刘春枝, 胡亚楠, 宋丹

作者信息 +

Efficacy and safety of less invasive surfactant administration in the treatment of neonatal respiratory distress syndrome: a Meta analysis

HUO Meng-Yue, MEI Hua, ZHANG Yu-Heng, LIU Chun-Zhi, HU Ya-Nan, SONG Dan

Author information +

文章历史 +

摘要

目的系统评价低侵入性肺表面活性物质治疗（LISA）技术在新生儿呼吸窘迫综合征（NRDS）中的有效性及安全性。方法计算机检索PubMed、Cochrane图书馆、Embase、中国生物医学文献数据库、中文科技期刊数据库（维普）、中国知网和万方数据库等，检索关于使用LISA技术治疗NRDS的随机对照试验（RCT）研究。依据文献纳入和排除标准进行文献筛选和质量评价。采用Review Manager 5.3统计软件进行Meta分析。结果共纳入9项RCT研究，合计1 212例NRDS患儿，其中试验组（使用LISA技术）611例，对照组（使用INSURE技术）601例。Meta分析结果显示：使用LISA技术降低了NRDS患儿生后72 h内机械通气率（OR=0.39，95%CI：0.29~0.51，P < 0.001）、支气管肺发育不良发生率（OR=0.53，95%CI：0.38~0.72，P < 0.001）及气胸发生率（OR=0.56，95%CI：0.33~0.93，P=0.02）。两组患儿病死率及其他新生儿疾病的发生率比较差异均无统计学意义（P > 0.05）。两组需要重复使用PS发生率比较差异无统计学意义（P > 0.05），用LISA技术观察到的PS反流发生率更高（OR=2.60，95%CI：1.64~4.12，P < 0.001）。结论与INSURE技术相比，LISA技术在减少NRDS患儿对机械通气需求，降低支气管肺发育不良及气胸的发生率方面具有优势。

Abstract

Objective To evaluate the efficacy and safety of less invasive surfactant administration (LISA) in the treatment of neonatal respiratory distress syndrome (NRDS). Methods PubMed, Cochrane Library, Embase, China Biology Medicine disc, China Scientific Journal Database, CNKI Database, and Wanfang Database were searched for randomized controlled trials (RCTs) on the use of LISA strategy in the treatment of NRDS. Literature screening and quality assessment were performed according to inclusion and exclusion criteria. Review Manager 5.3 software was used to perform the Meta analysis. Results A total of 9 RCTs were included, with a total of 1 212 children with NRDS. There were 611 children in the experimental group (treated with LISA strategy) and 601 children in the control group[treated with intubation-surfactant-extubation (INSURE) strategy]. The Meta analysis showed that the use of LISA strategy reduced the rate of mechanical ventilation within 72 hours after birth (OR=0.39, 95% CI:0.29-0.51, P < 0.001) and the incidence rates of bronchopulmonary dysplasia (OR=0.53, 95% CI:0.38-0.72, P < 0.001) and pneumothorax (OR=0.56, 95% CI:0.33-0.93, P=0.02). There were no significant differences in the mortality rate and incidence rates of other neonatal diseases between the two groups (P > 0.05). There was no significant difference in the rate of repeated use of pulmonary surfactant (PS) between the two groups (P > 0.05), but there was a higher incidence rate of PS reflux observed by LISA strategy (OR=2.60, 95% CI:1.64-4.12, P < 0.001). Conclusions Compared with INSURE strategy, LISA strategy has advantages in reducing the need for mechanical ventilation and the incidence rates of bronchopulmonary dysplasia and pneumothorax in children with NRDS.

导出引用

霍梦月, 梅花, 张钰恒, 刘春枝, 胡亚楠, 宋丹. 低侵入性肺表面活性物质治疗技术治疗新生儿呼吸窘迫综合征有效性和安全性的Meta分析[J]. 中国当代儿科杂志. 2020, 22(7): 721-727 https://doi.org/10.7499/j.issn.1008-8830.2001043

HUO Meng-Yue, MEI Hua, ZHANG Yu-Heng, LIU Chun-Zhi, HU Ya-Nan, SONG Dan. Efficacy and safety of less invasive surfactant administration in the treatment of neonatal respiratory distress syndrome: a Meta analysis[J]. Chinese Journal of Contemporary Pediatrics. 2020, 22(7): 721-727 https://doi.org/10.7499/j.issn.1008-8830.2001043

参考文献

[1] Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome-2019 update[J]. Neonatology, 2019, 115(4):432-450.
[2] Chun J, Sung SI, Ho YH, et al. Prophylactic versus early rescue surfactant treatment in preterm infants born at less than 30 weeks gestation or with birth weight less than or equal 1,250 grams[J]. J Korean Med Sci, 2017, 32(8):1288-1294.
[3] Klotz D, Porcaro U, Fleck T, et al. European perspective on less invasive surfactant administration-a survey[J]. Eur J Pediatr, 2017, 176(2):147-154.
[4] Wyckoff MH, Aziz K, Escobedo MB, et al. Part 13:neonatal resuscitation:2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care[J]. Circulation, 2015, 132(18 Suppl 2):S543-S560.
[5] Kanmaz HG, Erdeve O, Canpolat FE, et al. Surfactant administration via thin catheter during spontaneous breathing:randomized controlled trial[J]. Pediatrics, 2013, 131(2):e502-e509.
[6] Mirnia K, Heidarzadeh M, Hosseini MB, et al. Comparison outcome of surfactant administration via tracheal catheterization during spontaneous breathing with insure[J]. Med J Islamic World Acad Sci, 2013, 21(4):143-148.
[7] Bao Y, Zhang G, Wu M, et al. A pilot study of less invasive surfactant administration in very preterm infants in a Chinese tertiary center[J]. BMC Pediatr, 2015, 15:21.
[8] Mohammadizadeh M, Ardestani AG, Sadeghnia AR. Early administration of surfactant via a thin intratracheal catheter in preterm infants with respiratory distress syndrome:feasibility and outcome[J]. J Res Pharm Pract, 2015, 4(1):31-36.
[9] Kribs A, Roll C, Göpel W, et al. Nonintubated surfactant application vs conventional therapy in extremely preterm infants:a randomized clinical trial[J]. JAMA Pediatr, 2015, 169(8):723-730.
[10] Halim A, Shirazi H, Riaz S, et al. Less invasive surfactant administration in preterm infants with respiratory distress syndrome[J]. J Coll Physicians Surg Pak, 2019, 29(3):226-330.
[11] Göpel W, Kribs A, Ziegler A, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV):an open-label, randomised, controlled trial[J]. Lancet, 2011, 378(9803):1627-1634.
[12] 游芳, 任雪云, 牛峰海, 等. LISA技术与INSURE技术在早产儿呼吸窘迫综合征应用疗效的比较[J]. 中华新生儿科杂志(中英文), 2019, 34(4):254-258.
[13] 卢维城, 魏海波, 陈有平. 经胃管微创注入肺表面活性物质在新生儿呼吸窘迫综合征中的应用[J]. 广东医学, 2016, 37(21):3233-3235.
[14] 刘慧强, 童笑梅, 韩彤妍, 等. 微创应用肺表面活性物质治疗早产儿呼吸窘迫综合征失败的高危因素分析[J]. 中国当代儿科杂志, 2020, 22(3):231-237.
[15] Kurepa D, Perveen S, Lipener Y, et al. The use of less invasive surfactant administration (LISA) in the United States with review of the literature[J]. J Perinatol, 2019, 39(3):426-432.
[16] Barkhuff WD, Soll RF. Novel surfactant administration techniques:will they change outcome?[J]. Neonatology, 2019, 115(4):411-422.
[17] Kribs A. Minimally invasive surfactant therapy and noninvasive respiratory support[J]. Clin Perinatol, 2016, 43(4):755-771.
[18] Gortner L, Schüller SS, Herting E. Review demonstrates that less invasive surfactant administration in preterm neonates leads to fewer complications[J]. Acta Paediatr, 2018, 107(5):736-743.
[19] Härtel C, Paul P, Hanke K, et al. Less invasive surfactant administration and complications of preterm birth[J]. Sci Rep, 2018, 8(1):8333.
[20] Langhammer K, Roth B, Kribs A, et al. Treatment and outcome data of very low birth weight infants treated with less invasive surfactant administration in comparison to intubation and mechanical ventilation in the clinical setting of a cross-sectional observational multicenter study[J]. Eur J Pediatr, 2018, 177(8):1207-1217.
[21] Teig N, Weitkämper A, Rothermel J, et al. Observational study on less invasive surfactant administration (LISA) in preterm infants <29 weeks-short and long-term outcomes[J]. Z Geburtshilfe Neonatol, 2015, 219(6):266-273.
[22] Kaniewska U, Gulczyńska E. The influence of the technique of surfactant administration (LISA vs INSURE) on the outcomes of respiratory distress syndrome treatment in preterm infants[J]. Dev Period Med, 2019, 23(3):163-171.
[23] Göpel W, Kribs A, Härtel C, et al. Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants[J]. Acta Paediatr, 2015, 104(3):241-246.
[24] Herting E, Härtel C, Göpel W. Less invasive surfactant administration (LISA):chances and limitations[J]. Arch Dis Child Fetal Neonatal Ed, 2019, 104(6):F655-F659.